Millennium Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.9M | Buy |
41,300
+16,300
| +65% | +$12.5M | 0.01% | 1176 |
|
|
2025
Q4 | $19.3M | Sell |
25,000
-34,100
| -58% | -$23.2M | 0.01% | 1613 |
|
|
2025
Q3 | $33.2M | Buy |
59,100
+20,900
| +55% | +$11.8M | 0.01% | 1173 |
|
|
2025
Q2 | $20.1M | Sell |
38,200
-2,700
| -7% | -$1.51M | 0.01% | 1564 |
|
|
2025
Q1 | $25.9M | Sell |
40,900
-18,300
| -31% | -$12.6M | 0.01% | 1271 |
|
|
2024
Q4 | $42.2M | Sell |
59,200
-86,800
| -59% | -$72.8M | 0.02% | 902 |
|
|
2024
Q3 | $153M | Buy |
146,000
+32,700
| +29% | +$36.4M | 0.07% | 262 |
|
|
2024
Q2 | $119M | Sell |
113,300
-22,200
| -16% | -$21.5M | 0.06% | 361 |
|
|
2024
Q1 | $130M | Sell |
135,500
-49,500
| -27% | -$47.1M | 0.06% | 347 |
|
|
2023
Q4 | $162M | Sell |
185,000
-21,800
| -11% | -$18M | 0.07% | 239 |
|
|
2023
Q3 | $170M | Buy |
206,800
+49,400
| +31% | +$38.8M | 0.09% | 171 |
|
|
2023
Q2 | $113M | Buy |
157,400
+20,500
| +15% | +$15.8M | 0.06% | 304 |
|
|
2023
Q1 | $112M | Sell |
136,900
-93,900
| -41% | -$70.8M | 0.06% | 293 |
|
|
2022
Q4 | $167M | Buy |
230,800
+24,700
| +12% | +$18.2M | 0.09% | 185 |
|
|
2022
Q3 | $142M | Buy |
206,100
+2,400
| +1% | +$1.51M | 0.08% | 197 |
|
|
2022
Q2 | $120M | Sell |
203,700
-25,300
| -11% | -$16.4M | 0.07% | 219 |
|
|
2022
Q1 | $160M | Sell |
229,000
-61,800
| -21% | -$39.1M | 0.08% | 168 |
|
|
2021
Q4 | $184M | Buy |
290,800
+4,200
| +1% | +$2.58M | 0.09% | 173 |
|
|
2021
Q3 | $173M | Buy |
286,600
+157,600
| +122% | +$97.8M | 0.1% | 142 |
|
|
2021
Q2 | $72.1M | Buy |
129,000
+23,700
| +23% | +$12M | 0.04% | 441 |
|
|
2021
Q1 | $49.8M | Buy |
105,300
+16,300
| +18% | +$7.94M | 0.04% | 496 |
|
|
2020
Q4 | $43M | Buy |
89,000
+26,500
| +42% | +$14.3M | 0.03% | 537 |
|
|
2020
Q3 | $35K | Buy |
62,500
+27,500
| +79% | +$16.7M | 0.04% | 485 |
|
|
2020
Q2 | $21.8M | Buy |
35,000
+2,200
| +7% | +$1.25M | 0.03% | 679 |
|
|
2020
Q1 | $16M | Buy |
32,800
+17,800
| +119% | +$7.34M | 0.04% | 557 |
|
|
2019
Q4 | $5.63M | Buy |
+15,000
| New | +$5.05M | 0.01% | 1833 |
|
|
2019
Q3 | – | Sell |
-18,200
| Closed | -$5.7M | – | 4487 |
|
|
2019
Q2 | $5.7M | Buy |
+18,200
| New | +$6.06M | 0.01% | 1673 |
|
|
2017
Q3 | – | Sell |
-40,000
| Closed | -$19.6M | – | 3806 |
|
|
2017
Q2 | $19.6M | Buy |
+40,000
| New | +$17.5M | 0.04% | 681 |
|
|
2016
Q4 | – | Sell |
-25,000
| Closed | -$10.1M | – | 3655 |
|
|
2016
Q3 | $10.1M | Buy |
+25,000
| New | +$10M | 0.02% | 922 |
|
|
2014
Q1 | – | Sell |
-1,800
| Closed | -$495K | – | 3814 |
|
|
2013
Q4 | $495K | Sell |
1,800
-2,500
| -58% | -$719K | ﹤0.01% | 2720 |
|
|
2013
Q3 | $1.34M | Buy |
+4,300
| New | +$1.13M | ﹤0.01% | 1926 |
|
Other funds holding REGN
VCM
N
Millennium Management's REGN Position: Q1 2026 in Review
Millennium Management reduced its Regeneron Pharmaceuticals (REGN) stake by 83% in Q1 2026, selling an estimated $243M and leaving 62,730 shares worth $48.5M. The position accounts for 0.02% of the portfolio, ranked #848.
Millennium Management first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $293M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Millennium Management held 62,730 shares of Regeneron Pharmaceuticals worth $48.5M as of Q1 2026.
- Millennium Management sold 317,038 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $243M.
- Regeneron Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #848 holding.
- Millennium Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Millennium Management's Regeneron Pharmaceuticals position peaked at $293M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.